Hyper-CVAD/MA方案治疗复发或难治性非霍奇金淋巴瘤临床分析  

Hyper-CVAD/MA regimen in the treatment of relapsed or refractory non-Hodgkin's lymphoma

作　　者：王伟[1] 周学义[1] 薛玉宝[1] 朱子元[1] 史会昌[1] 刘淮东[1] 杨飞[1] 

机构地区：[1]江苏省淮安市第二人民医院肿瘤内科,江苏淮安223002

出　　处：《现代肿瘤医学》2010年第11期2225-2227,共3页Journal of Modern Oncology

摘　　要：目的:评价hyper-CVAD/MA方案治疗复发或难治性非霍奇金淋巴瘤的疗效、安全性和不良反应。方法:24例复发或难治性非霍奇金淋巴瘤患者采用hyper-CVAD/MA方案治疗。化疗每28天循环1个周期,下一周期治疗前评价疗效,每周评价不良反应。结果:24例患者中,总有效率为75%,其中CR 11例(45.83%),PR 7例(29.17%),1例(4.1%)患者因疾病进展死亡。1年无进展生存(PFS)率为50.11%,1年总生存(OS)率为79.8%。不良反应主要为化疗相关的血液学不良反应,均可耐受。结论:hyper-CVAD/MA方案治疗复发或难治性非霍奇金淋巴瘤,近期疗效满意,治疗相关不良反应易于控制,值得临床推广。Objective：To evaluate the safety and efficacy of hyper-CVAD/MA regimen in the treatment for relapsed or refractory non-Hodgkin＇s lymphoma.Methods： All 24 patients with relapsed or refractory non-Hodgkin＇s lymphoma were treated by hyper-CVAD/MA regimen.Results： The overall response rate of 24 cases of patients was 75%,including 11 cases（45.83%） complete response,7 cases（29.17%） patial response,1（4.1%） patient died of disease progression.One-year progression-free survival（PFS） was 50.11%,one-year overall survival rate was 79.8%.Adverse reactions mainly including chemotherapy-related hematologic toxicity and could be tolerated.Conclusion： The hyper-CVAD/MA regimen has a satisfying short-term therapeutic effect on patients with relapsed or refractory non-Hodgkin＇s lymphoma,the side effects coulol be controled.

关 键 词：hyper-CVAD/MA方案 复发或难治性 非霍奇金淋巴瘤 安全性 疗效 

分 类 号：R733.4[医药卫生—肿瘤]